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ABSTRACT
Chronic lymphocytic leukemia (B-CLL) and small lymphocytic lymphoma 
(SLL) are part of the same disease classification but are defined by differential 
distribution of tumor cells. B-CLL is characterized by significant immune suppression 
and dysregulation but this is not typical of patients with SLL. Natural killer cells 
(NK) are important mediators of immune function but have been poorly studied in 
patients with B-CLL/SLL. Here we report for the first time the NK cell phenotype and 
function in patients with B-CLL and SLL alongside their transcriptional profile. We 
show for the first time impaired B-CLL NK cell function in a xenograft model with 
reduced activating receptor expression including NKG2D, DNAM-1 and NCRs in-vitro. 
Importantly, we show these functional differences are associated with transcriptional 
downregulation of cytotoxic pathway genes, including activating receptors, adhesion 
molecules, cytotoxic molecules and intracellular signalling molecules, which remain 
intact in patients with SLL. In conclusion, NK cell function is markedly influenced by 
the anatomical site of the tumor in patients with B-CLL/SLL and lymphocytosis leads 
to marked impairment of NK cell activity. These observations have implications for 
treatment protocols which seek to preserve immune function by limiting the exposure 
of NK cells to tumor cells within the peripheral circulation.
INTRODUCTION
Chronic lymphocytic leukemia (B-CLL) and 
small lymphocytic lymphoma (SLL) have identical 
morphological and immunophenotypic features on tissue 
biopsy and are grouped together within the World Health 
Organization classification of hematological malignancy 
(WHO 2008) [1]. B-CLL is defined by peripheral blood 
lymphocytosis, bone marrow infiltration, and a variable 
degree of lymph node expansion [2, 3]. In contrast, 
patients with SLL do not demonstrate lymphocytosis and 
have a low incidence of cytopenias secondary to bone 
marrow infiltration [2]. The mechanisms underlying this 
differential distribution of tumor cells are not known but 
are likely to relate to fundamental properties of the tumor 
cell, such as chemokine receptor expression [4]. SLL is 
approximately ten times less common than B-CLL and 
accounts for 6% of all Non-Hodgkin lymphoma [5]. 
B-CLL is associated with a range of immunological 
complications including an increased propensity to infection 
and auto-immune complications [3, 6, 7]. In contrast, these 
complications are not a major feature of SLL [8] and most 
likely reflect differences in the tissue distribution of the 
tumor cells rather than the overall tumor load. A number 
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of immunological abnormalities have been described in 
patients with B-CLL including hypogammaglobulinaemia 
and T cell dysfunction [9]. Natural killer cells (NK cells) are 
innate lymphocytes that play a critical role in the immune 
surveillance against infection and malignancy and also 
contribute to the therapeutic activity of current treatment 
protocols for B-CLL/SLL [10]. However, the phenotype and 
function of NK cells in patients with B-CLL and SLL have 
been relatively poorly investigated. Tumors evolve many 
mechanisms to evade elimination by NK cells [11, 12], and 
defects in the cytotoxic capacity of NK cells from patients 
with B-CLL were described as early as 1996 [13]. The 
mechanisms that underlie this phenotype remain uncertain 
but are thought to reflect an alteration in the balance 
between activatory and inhibitory signaling [14–16]. 
We investigated the in vitro and in vivo function of 
NK cells from patients with B-CLL and SLL and observed 
a selective and marked functional impairment in cells 
taken from patients with B-CLL. Global downregulation of 
several activating receptors, including NKG2D, DNAM-1 
and NCRs, was observed on NK cells from patients with 
B-CLL. Using whole genome transcription microarray 
of NK cells, the transcription of many genes involved 
in cytotoxic function was also found to be dysregulated. 
These data reveal a profound and selective impairment 
of NK cell function in patients with B-CLL compared to 
those with SLL. The differential distribution of the B-CLL/
SLL tumor within blood is therefore a critical determinant 
of NK cell function. These data are relevant to the potential 
detrimental influence of lymphocytosis during ‘watch and 
wait’ clinical monitoring or during treatments with targeted 
therapies that mobilize tumors cells into the bloodstream. 
RESULTS 
NK cells from patients with B-CLL demonstrate 
functional impairment during assays of in vitro 
and in vivo activity
In order to investigate the functional capacity of 
NK cells taken from patients with B-CLL, an in-vitro 
cytotoxicity assay was carried out using the NK cell target 
line K562 [17]. NK cells were isolated from healthy donors 
(HD-NK) or patients with B-CLL (CLL-NK) prior to 
incubation with CFSE-labeled K562 cells. 43% of target 
cells were lysed following incubation with HD-NK cells 
(mean ± SEM: 43% ± 3.5%) but this was reduced by 
40% following incubation with CLL-NK (mean ± SEM: 
25.8% ± 2.6; p = 0.0017) (Figure 1A). This result has been 
confirmed by using Europium release based cytotoxicity 
assay (Supplementary Figure S1). In contrast, NK cells 
from patients with SLL demonstrated no significant 
difference in their lytic capacity compared to NK cells from 
HD (mean ± SEM: 41.7% ± 4.9; P = 0.56) (Figure 1A).
In order to assess how this impairment in vitro 
function was translated into activity in vivo we next used 
a xenograft model of NK cytotoxicity. NOG mice were 
injected subcutaneously with K562 cells and then at day 
3 NK cells, from either HD or patients with B-CLL, were 
infused. IL-2 was given to support NK cell expansion and 
a control group of mice received IL-2 treatment alone. 
K562 tumor growth became apparent in all mice at day 7 
after injection and tumor size was measured on day 10, 14 
and 17 (Figure 1B). NK cells taken from HD substantially 
reduced the growth of the K562 tumor such that tumor 
volume was suppressed by 54% at day 17. Tumor sizes 
derived from control mice were 1910 ± 290 mm3 (mean ± 
SEM) compared to 890 ± 200 mm3 in those mice infused 
with HD-NK cells (p = 0.029) (Figure 1C). In contrast, NK 
cells taken from patients with B-CLL were incapable of 
any significant degree of tumor suppression (Figure 1C).
NKG2D expression and NKG2D-mediated 
cytotoxic function are both decreased in NK cells 
taken from patients with B-CLL but not SLL
NK cell cytotoxicity is mediated through a range 
of activating receptors, of which NKG2D-mediated 
signaling is a dominant pathway. As such, we next went 
on to determine the surface expression of NKG2D on NK 
cells taken from HD and patients with B-CLL (n = 23). 
A markedly reduced expression of NKG2D was observed 
on NK cells from patients with B-CLL but not SLL, in 
comparison to the profile on cells from HD (Figure 2A). 
In particular, the percentage of NKG2D-positive NK 
cells was reduced by 51% amongst patients with B-CLL 
(mean ± SEM B-CLL 43.1% ± 2.7% vs HD 86.6% ± 2.7%; 
p < 0.001; Figure 2B). Interestingly, the percentage of 
NKG2D positive NK cells was not reduced in patients 
with SLL (mean ± SEM 85.3% ± 2.9%) in comparison to 
that observed on NK cells from HD (Figure 2B).
In order to assess if this reduction of NKG2D 
surface expression on NK cells from patients with 
B-CLL is functionally significant we then determined 
the ability of NK cells to mediate NKG2D-dependent 
cytotoxicity. Specifically, a CHO cell line was stably 
transfected with ULBP6, an NKG2D ligand, and was 
used as a target cell, whilst untransfected CHO cells 
served as a negative control. The cytotoxicity to this 
cell line has been shown to be able to be blocked by 
anti-NKG2D antibody (Supplementary Figure S4). 
NKG2D-mediated killing was substantially reduced 
using NK cells from patients with B-CLL in comparison 
to either NK cells taken from HD or patients with 
SLL. In particular, specific lysis of the ULBP6-
expressing CHO cell line by NK cells from HD was 
47% compared to only 29% using NK cells taken 
from patients with B-CLL (mean ± SEM: HD 47% ± 
7.0% vs B-CLL, 29% ± 5.4% p < 0.05) (Figure 2C). 
Again, NK cells taken from patients with SLL did not 
reveal any impairment of lytic activity compared to HD 
(mean  ± SEM SLL 48.5% ± 6.1%) (Figure 2C). 
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The expression of DNAM-1 and natural 
cytotoxicity receptors are also reduced on NK 
cells from patients with B-CLL but not SLL
In addition to NKG2D, several other activating 
receptors are expressed on NK cells, including DNAM- 1 
and the natural cytotoxicity receptors (NCR) NKp30 and 
NKp46. The surface expression of DNAM-1, NKp30 
and NKp46 was examined on NK cells taken from HD 
and patients with B-CLL or SLL. All three activating 
receptors were markedly downregulated on NK cells from 
patients with B-CLL compared to NK cells from HD. Of 
note, the percentage of DNAM-1 positive NK cells was 
89.3% ± 1.1% on HD-NK compared to 75.5% ± 2.9% 
on CLL- NK cells (p < 0.001) (Figure 3A left panel). 
Similarly, the percentage of NKp46 positive NK cells was 
58.3% ± 3.3% on HD-NK compared to 35.4% ± 3.2% on 
CLL-NK cells (p < 0.001) (Figure 3A middle panel). Also 
the percentage of NKp30 positive NK cells was 73.6% 
± 4.2% and 61.1% ± 4.0% (p = 0.0152) on HD-NK and 
Figure 1: NK cells from patients with B-CLL fail to control tumor growth in vitro and in vivo. (A): NK cells were enriched 
and co-cultured with CFSE-labelled K562 cells for 16hrs. The cytotoxicity was calculated according to the relative cell count of the live 
populations of target cells using flow cytometry. Data shown are mean values of the specific cytotoxicity from 12 healthy donors (HD), 
12 patients with B-CLL and 8 patients with SLL. Error bars represent standard errors and significance was determined using Mann-Whitney 
testing. p < 0.01(**). (B–C): NOG (NOD/Shi-scid/IL-2Rg) mice were injected subcutaneously with 1 × 107 K562 cells and divided into 
3 groups which were given either IL-2 only (control), IL-2 with HD-NK cells or IL-2 with CLL-NK cells. Tumour growth was monitored 
and measured regularly. The tumour growth curve (B) of the three groups are shown as mean values of the tumour size from 4 mice at 
different time points in each group, error bars represent standard errors. The tumour size at day 17 was compared among three groups (C). 
Error bars represent standard errors and significance was determined using Mann-Whitney testing. p < 0.05(*). 
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CLL-NK cells respectively (Figure 3A right panel). In 
contrast, the percentage of these receptors positive NK 
cells from patients with SLL was not significantly different 
from those found on HD-NK (DNAM-1, 86.0% ± 
2.3%; NKp46, 59.2% ± 6.7%; NKp30, 68.0% ± 8.3%) 
(Figure 3A). Together, these data show that expression of 
activating receptors is substantially reduced on NK cells 
taken from patients with B-CLL, but not from patients 
with SLL. Also the mean fluorescence intensity (MFI) 
of surface expression of NKG2D, DNAM-1 and NCRs 
showed similar trend of reduction on NK cells from 
patients with B-CLL, but not from patients with SLL 
(Supplementary Figure S3).
NK cells from patients with B-CLL express lower 
levels of CD16 and display impaired antibody-
dependent cell mediated cytotoxicity (ADCC)
The Fc receptor, CD16, is an activating receptor 
expressed on the majority of NK cells and plays an 
important role in mediating ADCC. The pattern of 
CD16 expression was next examined on NK cells from 
patients with B-CLL and SLL (gating strategy shown in 
Supplementary Figure S5). 75.7% ± 3.5% of NK cells 
from HD were CD16bright, compared to only 39.0% ± 5.3% 
of NK cells derived from patients with B-CLL (p < 0.001) 
(Figure 3B). The percentage of CD16bright NK cells in 
Figure 2: Expression of NKG2D on NK cells is downregulated in patients with B-CLL but not patients with SLL. 
(A) An example of flow cytometry staining of the surface NKG2D expression on NK cells from one healthy donor (HD), one patient with 
B-CLL and one patient with SLL. Solid black lines represent NKG2D staining and grey-filled histograms represent isotype control staining. 
(B) The NKG2D surface expression on NK populations from 23 HD, 23 patients with B-CLL and 8 patients with SLL were studied. The 
percentage of NKG2D positive NK cells is shown, with error bars representing standard errors and the significance determined using Mann-
Whitney testing, p < 0.001(***). (C) For the NKG2D specific NK cytotoxicity assay, a mixture of NKG2D ligand-transfected CHO cells 
and control transfected CHO cells were co-incubated with effectors for 16 hrs. After co-culture, the ratio of control CHO cells to NKG2DL-
transfected CHO cells was calculated to determine the percentage of specific killing. Data shown are median values of specific cytotoxicity 
from 7 HD, 7 patients with B-CLL and 6 patients with SLL. Bars represent minimal and maximal values of the data and significance was 
determined using Mann-Whitney testing, p < 0.05(*). 
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patients with SLL (79.1% ± 2.9) was not different to 
HD-NK cells (Figure 3B).
ADCC is an important effector mechanism 
underlying the activity of rituximab, a CD20-specific 
monoclonal antibody used in the management of 
B-CLL[18]. In order to assess if the reduction in the 
proportion of CD16bright NK cells from patients with 
B-CLL might impact on rituximab efficacy, a rituximab-
sensitized ADCC in vitro assay was undertaken, with 
primary allogeneic B-CLL tumor cells used as targets. In 
the absence of rituximab, killing of B-CLL tumor cells 
was relatively modest regardless of the source of NK cells, 
reflecting natural resistance of primary B-CLL tumor cells 
to NK cell mediated lysis. However, even here tumor 
cell killing was reduced using NK cells from patients 
with B-CLL (2.2% ± 1.3) compared to NK cells from 
HD (15.7% ± 3.2) or patients with SLL (23.4% ± 4.0) 
(Figure 3C). The addition of rituximab led to a substantial 
increase in tumor lysis by all three NK effector subgroups 
(they are all allogeneic NK cells against a single clone 
of primary tumor cells). However, although tumor 
killing by CLL-NK cells increased by nearly 20- fold 
following rituximab, from 2.2% to 43%, this was still 
significantly lower than the lysis observed with rituximab 
in combination with NK cells from HD and patients with 
SLL (69% and 58% respectively) (Figure 3C). Similar 
results has been obtained using the enriched B cells from 
healthy donors as target cells (Supplementary Figure S6). 
These results indicate that allogeneic NK cells from 
patients with B-CLL demonstrate reduced lysis of primary 
B-CLL cells, which is partially but not completely, 
enhanced in the setting of ADCC. 
Figure 3: Expression of DNAM-1, natural cytotoxicity receptors and CD16 are also reduced on NK cells from patients 
with B-CLL. (A) The surface expression of DNAM-1 (left panel), NKp46 (middle panel) and NKp30 (right panel) was determined on 
NK cells from 23 healthy donors (HD), 23 patients with B-CLL and 8 patients with SLL were studied using flow cytometry. Data shown 
are mean values for the percentage of cells positive for each receptor within HD, patients with B-CLL and patients with SLL. Error bars 
represent standard errors and significance was determined using Mann-Whitney testing, p < 0.05(*) and p < 0.001(***). (B) The expression 
of CD16 was determined on NK cells from 23 HD, 23 patients with B-CLL and 8 patients with SLL using flow cytometry. Data shown 
are mean values of the percentage of CD16 bright populations of NK cells from HD, patients with B-CLL and patients with SLL. Error bars 
represent standard errors and significance was determined using Mann-Whitney testing, p < 0.001(***). (C) For the rituximab induced NK 
cytotoxicity assay, B-CLL primary tumor cells were enriched and used as target cells. The target cells were then incubated NK cells, with 
or without Rituximab, for 16 hours. Specific lysis was calculated according to the relative cell counting using flow cytometry. Data shown 
are mean values of the specific cytotoxicity by NK cells from 7 HD, 7 patients with B-CLL and 6 patients with SLL. Error bars represent 
standard errors and significance was determined using Mann-Whitney testing, P < 0.05(*), and P < 0.01(**). 
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The transcriptional profiles of NK cells from 
patients with either B-CLL or SLL display a 
unique profile
To investigate the transcriptional basis for the 
functional and phenotypic impairment of NK cells 
from patients with B-CLL, we used GeneChip® Human 
Transcriptome Array 2.0. and performed comparative 
transcriptional profiling of NK cells taken from HD or 
patients with either B-CLL or SLL (n = 5 in each group). 
70523 positive probe-sets were found among the whole 
chip-set. 
The pattern of gene expression within NK cells 
from patients with B-CLL or SLL was compared to the 
transcriptional profile observed in NK cells taken from 
HD. 480 and 667 genes showed at least a 1.5 fold change 
in transcript levels within CLL-NK and SLL-NK samples 
respectively compared to HD-NK (p < 0.05). However, it 
was noteworthy that the great majority of these differences 
were not shared between patients with SLL and B-CLL. 
In particular, 331 genes were downregulated in CLL-NK 
samples and 189 genes were downregulated within the 
SLL-NK group. However, only 46 of these genes shared 
a common pattern of downregulation within both groups 
(Figure 4A middle panel, Figure 4B top panels). A further 
149 and 478 genes demonstrated increased expression 
within CLL-NK and SLL-NK samples respectively, 
whilst only 36 genes were upregulated in both patient 
groups (Figure 4A right panel, Figure 4B bottom panels). 
Together, 93 shared genes were significantly modified 
within both groups compared to HD-NK (Figure 4A left 
panel). 46 of these shared genes were downregulated, 36 
were upregulated in both groups and 11 differed in their 
direction between the two groups. DAVID functional 
annotation tool was then used to identify gene sets of GO 
(Gene ontology terms) that were enriched. Consistent 
transcription changes were observed within each sample 
of the three participant groups. The 93 genes included 
genes encoding phosphoproteins (38 genes), regulation 
of transcription (15 genes), intracellular signaling cascade 
(11 genes) and regulation of apoptosis (9 genes) (Figure 4A 
left panel and Supplementary Figure S7). 
Multiple genes involved in NK cytotoxicity are 
expressed at lower level in NK cells from patients 
with B-CLL
We next determined the biochemical pathways that 
are modulated by the pattern of trancriptional expression 
within NK cells. KEGG pathway analysis (http://www.
genome.jp/kegg/pathway.html) highlighted the gene group 
responsible for NK cell-mediated cytotoxicity that were 
downregulated by more than 1.5 fold within CLL- NK 
samples compared to HD-NK (p < 0.05). These were 
then grouped into four classes, based on the NK cytotoxic 
pathway (Figure 5B), namely activating receptors (NCR1, 
NCR3, FCGR3A, FCGR3B, FCER1G, HCST), adhesion 
molecules (NCAM1, ITGAL, ITGB2, SPN, ITGAM), 
cytotoxicity molecules (GZMA, GZMB, GZMK, PRF1) 
and genes involved in the cytotoxic intracellular signaling 
cascade (NFATC2, SYK, VAV1, RAC2, PRKCA, PRKCB, 
LAT2) (Figure 5A). These data indicate that several 
biochemical pathways important for cytotoxic funcion are 
imparied in NK cells from patients with B-CLL.
The profile of these genes was next examined in NK 
cells taken from patients with SLL and, with the exception 
of VAV1 which was reduced by 48% in patients with SLL, 
all genes were found to be expressed at the same level 
as cells from HD (Figure 5A). These data are consistent 
with the substantial difference in the pattern of functional 
cytotoxicity observed between NK cells taken from 
patients with B-CLL or SLL. 
In order to assess how the transcriptional profile 
correlated with the pattern of surface expression, we next 
correlated microarray data with flow cytometric analysis. 
The relative transcription levels for NCR1 (NKP46) and 
NCR3 (NKp30) were 94 and 81 in HD-NK, 60 and 45 in 
CLL-NK and 123 and 93 in SLL-NK. As described above, 
these levels were significantly lower in CLL- NK cells 
compared to HD-NK and SLL-NK (P = 0.001 for NCR1 
and 0.0002 for NCR3) with no difference observed between 
HD-NK and SLL-NK. Interestingly, flow cytometric 
analysis of surface expression of NKp46 and NKp30 
revealed the same pattern, with MFI of 402 and 2650 
respectively in HD, 337 and 2060 in patients with B-CLL 
and 432 and 2240 in patients with SLL (Supplementary 
Figure S3). A further 5 cytotoxic-related genes, (NCAM1 
(CD56), FCGR3A (CD16a), FCGR3B (CD16b), PRF1 
(perforin) and GZMB (granzyme B), also exhibited a strong 
correlation between transcriptional profile and surface or 
intracellular protein expression (data not shown). 
Interestingly, the level of NKG2D transcription did 
not differ between CLL-NK and HD-NK cells. However, 
NKG2D is expressed as a dimer associated with the adaptor 
protein DAP10 [19, 20] and expression of the HCST 
gene, which encodes DAP10 was markedly reduced in 
CLL- NK cells compared with HD-NK and SLL-NK (mean 
transcription: HD-NK 240 vs CLL-NK 162 vs SLL- NK 
428 respectively) (Figure 5A). The association with 
DAP10 is a pre-requisite for NKG2D expression at the cell 
surface [21] and DAP10 phosphorylation is required for 
the intracellular signaling that mediates NK cell activation 
[22, 23]. As such, the reduction in DAP10 transcription in 
CLL-NK cells is sufficient to account for the observation 
of decreased NKG2D expression and impaired NKG2D-
specific killing by CLL-NK cells (Figure 2). 
DISCUSSION
NK cells have a critical role in the control of 
infection and malignant disease [24], but have been 
relatively poorly investigated in patients with B-CLL, 
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despite the observation that both of these complications 
are increased in this disorder. Our study has revealed 
significant functional impairment of NK cells from 
patients with B-CLL and used for the first time 
transcriptional and flow cytometric analysis to reveal 
multiple mechanisms in NK cytotoxicity impairment. 
Additionally, we show that NK cell cytotoxicity was 
unimpaired in patients with SLL, a clinical disorder that is 
defined as part of the same disease entity as B-CLL.
Impaired cytolytic function of NK cells in 
patients with B-CLL has previously been described 
[13, 16, 25, 26]. This impairment has been attributed to a 
lack of azurophilic granules, impaired release of cytolytic 
molecules [13], and impaired expression of activating 
receptors [16]. In agreement with others, our study has 
confirmed the impaired cytotoxic function of NK cells 
from patients with B-CLL in vitro using K562 target cells 
but have further extended this observation in vivo using a 
xenograft model. Importantly, we also for the first time use 
an NKG2D-dependent cytotoxicity assay to demonstrate 
that reduced NKG2D expression directly correlated with 
impairment in NK cell cytotoxicity (Figure 2C). 
Our microarray analysis contrasted the transcriptional 
profile of NK cells from HD or patients with either B-CLL 
or SLL and remarkably found that many genes, which 
regulate cytotoxicity are downregulated in NK cells 
taken from patients with B-CLL. These included NK 
activating receptors such as NKp30, NKp46 and several 
Figure 4: The transcription profile of NK cells in patients with B-CLL or SLL compared to healthy donors. (A) Venn 
diagram demonstrating the intersection of genes significantly modified in NK cells from patients with B-CLL or SLL compared to healthy 
donors (HD) in microarray analysis. The number of genes which show any significant change is shown in the left panel and the number 
of downregulated or upregulated genes are shown in the middle and right panels respectively. (B) Graphical representation of the relative 
transcriptional level of similarly or differentially expressed genes in NK cells from patients with B-CLL or SLL compared to HD. 46 genes 
are downregulated in NK cells from both patients with B-CLL and SLL compared with HD (top left graph) and 36 genes are upregulated in 
these groups (bottom left graph). 285 genes are downregulated in NK cells from patients with B-CLL compared to HD but not in patients 
with SLL (top right graph) whereas 113 genes are upregulated in NK cells from patients with B-CLL compared to HD, but not in patients 
with SLL (bottom right graph). 
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Figure 5: Multiple points in the cytotoxicity pathway of NK cells are impaired in patients with B-CLL. (A) This 
demonstrates the relative intensity profile of 22 genes related to NK cytoxic function which are downregulated in NK cells from patients 
with B-CLL compared to HD. Each column represents one sample, whilst each row represents the relative hybridization intensity of an 
individual gene. The 22 transcripts were classified into 4 categories (From the top to the bottom): NK activating receptors (6 genes), adhesion 
molecules (5 genes), cytotoxic molecules (4 genes) and intracellular signal transduction related molecules (7 genes). The colour on the 
heatmap indicates the magnitude of the relative expression of genes across the samples, with brighter red indicating higher expression and 
brighter green indicating lower expression. (B) The NK cell cytotoxicity pathway (adapted from KEGG pathways analysis). Highlighted 
genes in green are those that have been shown to be significantly downregulated in patients with B-CLL compared to HD. 
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adhesion molecules. Adhesion molecules are required for 
immunological synapse formation, which has been reported 
to be impaired in patients with B-CLL and improves with 
the use of lenolidamide [27]. We also found significant 
reduction in expression of genes involved in cell signalling 
and cytotoxic granule formation. The combination of these 
defects would all contribute to the impaired cytotoxic 
function observed in NK cells from patients with B-CLL. 
NK cells are believed to be important in the 
elimination of tumor cells. It is therefore not surprising 
that tumors evolve mechanisms to evade elimination 
by NK cells, including secretion of immunoregulatory 
molecules such as PGE2 and TGF-β [28, 29]. 
Confirming the findings of others, we incubated 
HD-NK cells with TGFβ-1 for 48hrs and found the 
surface expression of NKG2D was reduced by 53% 
(p = 0.014) (Supplementary Figure S8) [30, 31]. And 
also B-CLL tumor cells produce considerable amounts 
of TGF-β1, such that elevated levels are found in patient 
serum [32, 33]. Soluble TGF-β1 therefore represents one 
mechanism by which the functional impairment of NK 
cells in patients with B-CLL may arise. 
One of our most striking and novel observations 
was the profound difference in the profile of NK cell 
populations taken from patients with B-CLL or SLL. 
Indeed, NK cells from patients with SLL showed 
no significant impairment in function or phenotype 
compared to cells taken from HD. The clinical difference 
between B-CLL and SLL is the tissue distribution of the 
tumor cells. SLL is characterized by lymphadenopathy 
and/or splenomegaly in the absence of a peripheral 
lymphocytosis, whereas B-CLL is defined by the 
presence of tumor cells in the blood. As such, NK cells 
in patients with B-CLL will be exposed continually to 
tumor cells within the circulatory system where chronic 
signaling interactions, such as tumor cell expressing and 
shedding NKG2D and NCR ligands, will lead to NKG2D 
downregulation and potential NK ‘exhaustion’ [14, 34]. Of 
note we did not find any difference in the level of soluble 
NKG2D ligands within serum between HD and patients 
with B-CLL (Supplementary Figure S9). Interestingly, 
a murine model of NK cell adoptive transfer has also 
demonstrated the rapid down-regulation of activating 
receptors in a pattern that correlated with tumor exposure 
[35]. An overview of potential mechanisms is shown in 
Figure 6.
Our observations further suggest that NK cells do 
not interact significantly with tumor cells within lymph 
nodes in patients with SLL. During health, the great 
majority of NK cells circulate within the blood and 
demonstrate a cytolytic CD56dim phenotype. However a 
population of CD56hi NK cells is observed within lymph 
nodes where they differentiate from a CD34dimCD45RA+ 
hematopoietic precursor cell under the influence of IL-12 
or IL-15 [36–38]. We performed immunohistochemical 
analysis to determine NK cell expression in lymph node 
sections taken from patients with SLL (n = 6) or B-CLL 
at stage B disease (n = 2). Interestingly, CD56+ or CD16+ 
NK cells were completely absent in tumor lymph nodes, a 
pattern that was in marked contrast to the profile observed 
in healthy lymph node sections and has not previously 
been reported. No differences were observed between 
lymph node sections of SLL and B-CLL. 
GO (Gene ontology terms) analysis of the 
microarray result from DAVID functional annotation 
tool showed that there were 32 genes involved in 
cell migration, cell motion and chemokine signalling 
pathway are significantly modulated in B-CLL patients 
group compared with HD (Supplementary Figure S10). 
7 genes, VAV1, PRKCA, EPHA4, SELPLG, ID1, MYH9 
and CXCR3, were consistently modulated in both the 
B-CLL and SLL groups. Several of these proteins are 
Figure 6: Model of the potential mechanisms that underlie impairment of NK cytotoxicity in patients with B-CLL. 
Chronic exposure to B-CLL tumour cells within the circulation and high levels of TGF-β1 may serve to impair NK cell function in patients 
with B-CLL. 
Oncotarget68522www.impactjournals.com/oncotarget
involved in mediating signaling pathways that activate the 
actin cytoskeleton and cell migration. Two particularly 
interesting genes are CXCR3 and SELPLG (CD162) 
which play an important role in the migration of NK cells 
between the lymphoid compartment and peripheral tissues 
[39]. Together our data indicate that NK cells are largely 
unable to enter lymph nodes containing B-CLL/SLL tumor 
cells and that this helps to preserve peripheral NK cell 
function in patients with SLL. 
These data suggest that the function of the immune 
system is significantly less impaired in patients with 
SLL compared to those with B-CLL. Interestingly there 
has been relatively little study of comparative immune 
function and relative infection risk in patients with 
these two disorders. Reduced levels of IgM and IgG 
are observed in patients with SLL although the IgA 
concentration is well preserved [40], a factor that has been 
recently correlated with reduced infection risk in patients 
with B-CLL who have been treated with ibrutinib [41]. 
In contrast, the frequency of auto-immune hemolysis and 
thrombocytopenia is markedly less common in SLL but 
previous work has not found any evidence of difference 
in the T cell compartments between the two disease 
subsets [8, 42]. Although there are no epidemiological 
studies of the incidence of infectious complications, 
the widespread clinical impression is that these are less 
common in patients with SLL, and indeed other patients 
with low grade non Hodgkins lymphoma, than in patients 
with B-CLL. To our knowledge this work represents the 
first comparison of NK cell function from patients with 
SLL and B-CLL and suggests that preservation of NK 
cell function could play an important role in maintaining 
immune homeostasis in this disorder.
Strikingly, the changes described in this work 
were identified in patients with early stage B-CLL, in 
whom a ‘watch and wait’ approach to treatment is almost 
universally adopted. The findings add to the knowledge 
that clinical observation of early stage B-CLL is associated 
with gradual impairment of immune function [43] and may 
contribute to arguments in favour of the early control of 
the tumor clone. Indeed, downregulation of NKG2D on 
NK cells has been correlated with disease progression 
[16] but no such association was observed in our cohort 
due to the relatively early clinical stage of the patient 
group. The data are also of interest in relation to the use 
of signal transduction inhibitors, such as ibrutinib or 
idelalisib, which can induce a state of lymphocytosis for 
several months after treatment and which might therefore 
lead to further impairment of NK function. This suggests 
that combination therapy with agents such as anti-CD20 
antibodies, which control drug-induced lymphocytosis, 
may help to support NK cell function. However, further 
studies are needed in this regard and information to date 
has suggested that infectious complications and immune 
dysfunction are actually reduced in patients who are treated 
with these agents [41]. Our data suggests that interventions 
to improve NK cell function could be a promising 
strategy to improve the clinical outcome for patients with 
B-CLL. Indeed, it has been suggested that some of the 
clinical efficacy of lenalidomide in B-CLL derives from 
its ability to increase the expression of NKp30 on NK cells 
and increase tumor cell lysis [44]. In addition recombinant 
IL15 has also been shown to be presented by B-CLL tumor 
cells to NK cells in vitro where it leads to NK activation 
and subsequent tumor cell lysis [45]. 
In summary, we have demonstrated a profound 
functional impairment of cytotoxic activity in NK cells 
from patients with B-CLL and have shown for the first 
time using transcription profiling, that this arises as a 
result of a global impairment of several biochemical 
pathways within the cytotoxic machinery. Additionally, 
we show this pattern is not present in patients with SLL, 
indicating that NK cell function is determined primarily 
by the anatomical site of the tumor clone. This observation 
has significant implications for the development of future 
clinical protocols, which seek to optimize immune 
function in the management of B-CLL. 
MATERIALS AND METHODS
Participants
Patients with B-CLL were recruited from clinics at 
Birmingham Heartlands Hospital and University Hospital 
Birmingham over a 6 month period. Patients were assessed 
by an experienced Hematologist and fulfilled IWCLL 
criteria for B-CLL or WHO criteria for SLL. 23 Patients 
with B-CLL were confirmed to be untreated and Binet 
stage A at recruitment, with a median age of 70 years 
(IQR 63–81). 8 untreated Patients with SLL were also 
studied, with a median age of 70 years (IQR 59.8–76.3) 
and either palpable or CT evidence of lymphadenopathy 
which was histologically proven to be SLL, in the absence 
of a peripheral lymphocytosis. All patients provided 
written informed consent in accordance with ethical 
approval obtained from the local regional ethics committee 
(REC no 10/H1206/58). For comparative analysis, 
23 healthy age-matched donors were recruited as part 
of the ongoing 1000 elders recruitment at University of 
Birmingham, which recruits local healthy individuals who 
are over the age of 65. Their median age was 73 years 
(IQR 67–83.2). Written informed consent was obtained and 
50 ml of peripheral blood donated (REC no 2002/073). 
Immunophenotyping
Following all blood donations, peripheral blood 
mononuclear cells (PBMCs) were extracted over a ficoll 
density gradient and stored at −160oC. PBMCs were 
later defrosted and used for functional NK cell studies, 
immunophenotyping and NK cell enrichment prior to 
microarray analysis.
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After defrosting, PBMCs were washed and 
re- suspended at 106cells/100 μl before staining with live/
dead® red stain dye (Invitrogen; Massachusetts, USA). 
Cells were subsequently washed before incubation with one 
of the following antibody panels: NKG2D panel; anti-γδ 
PE, anti-CD3 FITC (Beckman Coulter, USA); anti-CD8 
Amcyan, anti-NKG2D APC (BD bioscience, USA), anti-
CD4 Percp-Cy5.5 (eBioscience, USA) anti-CD56 PE-Cy7 
(Biolegend, USA). DNAM panel; anti-γδ PE; anti-CD8 
Amcyan, anti-CD4 Percp-Cy5.5, anti-CD56 PE-Cy7, 
anti-DNAM FITC, (Biolegend) anti-CD3 APC-Cy7 
(BD bioscience) and anti-CD19 APC (eBioscience). NCR 
panel; anti-γδ PE; anti-CD8 Amcyan, anti-CD4 Percp-Cy5.5, 
anti-CD56 PE-Cy7, anti-CD3 APC-Cy7, anti-NKp46 Pacific 
Blue and anti-NKp30 APC (Biolegend,). All flow data 
unless specified was collected using the BD LSR II flow 
cytometer and analysed using BD FACSDiva® software 
(BD Biosciences) (gating strategy in Supplementary Figure 
S2). For comparison of phenotyping expression data between 
SLL, B-CLL and HD, non-parametric Mann-Whitney testing 
was performed. All analysis was performed using Prism 
version 6.0, Graphpad software, San Diego, USA.
In vitro NK cell cytotoxicity 
NK cells were purified using EasySep™ Human 
NK cell enrichment kit (Stem Cell Technologies, 
Canada) (purity of sorted NK was around 90–95% of 
CD3 negative and CD56 positive lymphocytes) and 
activated overnight at 37oC with Interferon-alpha (IFNα) 
(PeproTech, USA). For the K562 cytotoxicity assay, K562 
cells were labeled with CFSE dye. The labeled K562 cells 
were then either incubated with RPMI (negative control) 
or in combination with activated NK cells at an E/T 
ratio of 0.5:1 on a 96 well plate for 16 hours. Cells were 
subsequently extracted and a fixed volume analyzed on 
the BD Accuri™ flow cytometer (BD Bioscience) to gain 
a relative cell count. % specific lysis was calculated by 
100 × {1 – [(experimental group cell count)/(control cell 
count)]}. Propidium iodide dye was used for gating of the 
live and dead populations. 
For the NKG2D specific NK cytotoxicity assay, 
a 50:50 mixture of NKG2D ligand (ULBP6 (GenBank 
ID: AY039682.1) transfected Chinese hamster ovary 
(CHO) cell line labeled with carboxyfluorescein diacetate 
succinimidyl ester (CFSE) and control transfected CHO 
cells labeled with 670 dye, were co-incubated with effector 
cells (IFN-α activated PBMCs) for 16hrs. After co-culture, 
the ratio of CFSE negative (670 dye positive, control 
CHO cells) to CFSE positive cells (ULBP6 transfected 
CHO cells) was calculated to determine the percentage 
of specific killing. % specific lysis was calculated by 
100 × {1 − [(control ratio)/(experimental ratio)]}. The 
control ratios refer to the CFSE negative/CFSE positive 
without effectors cells, while the experimental ratio refers 
to the CFSE negative/CFSE positive with effectors cells. 
NKG2D blocking antibody (MAB139) was purchased 
from R&D system, and used at the concentration of 
10 ug/ml in the blocking experiment. 
For the rituximab-induced NK cytotoxicity assay, 
target cells including primary B cells from HD and 
the B-CLL primary tumor cells were enriched using 
EasySep™ Human B cell enrichment kit (Stem Cell 
Technologies, Canada). The target cells were then either 
incubated with RPMI (negative control) or in combination 
with activated NK cells with or without Rituximab, at an 
E:T ratio of 5:1 on a 96 well plate for 16 hours. Cells 
were subsequently extracted and stained with anti-CD5-
PE (Biolegend) and anti-CD19-FITC (Biolegend) to gate 
the B-CLL primary tumor cells and analysed on the BD 
Accuri™ flow cytometer to gain a relative cell count. 
The percentage of specific lysis was then calculated. 
Propidium iodide dye was used for gating of the live and 
dead populations. 
In-vivo NK cytotoxicity assay using xenograft 
NOD/SCID mouse model
The animal work was carried out under the 
Project license: 70/7793 and Personal License number: 
I031C5AD2. NOG (NOD/Shi-scid/IL-2Rg) mice were 
bred and maintained at the animal facility, University of 
Birmingham. The mice were treated for one week with 
baytril before tumor injection. At 8 weeks old, 12 NOG 
mice were irradiated with 1.25Gy. They were then injected 
subcutaneously with 1 × 107 K562 cells to the dorsal 
lateral thorax. 
At day 3, the mice were divided into 3 groups. Each 
group consisted of 4 mice and received either IL-2 only, 
IL-2 with 2 × 106 NK cells from HD or IL-2 with 2 × 106 
NK cells from Patients with B-CLL. The NK cells were 
injected intravenously through the tail vein. 
The mice were culled seventeen days after receiving 
the K562 cells. The subcutaneous tumors were then 
removed and fixed in formaldehyde. After fixation, tissues 
were cut into sections of 5 µm with a cryomicrotome and 
then paraffin embedded (performed by Queen Elizabeth 
Hospital UK). The slides were then deparaffinised and 
rehydrated. Antigen retrieval was performed using 
a citrate and EDTA buffer. Slides were then washed 
with a blocking agent and incubated with primary 
antibodies. Four primary antibodies were used: anti-
CD16, anti-CD56, anti-CD117 and anti-glycophorin C 
(Abcam, Cambridge, UK). After incubation, the slides 
were washed with PBS and monoclonal rabbit secondary 
antibodies were applied (Vector Laboratories, Burlingame 
CA, USA). The DAB solution (substrate buffer, DAB 
and chromogen) was then added before submerging 
in haematoxylin to counterstain nuclei. Images were 
obtained using a Nikon Eclipse 800 microscope. Tonsil 
controls were also used to optimize primary antibody 
concentrations and as a positive control.
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NK cell sorting and microarray gene 
transcription profiling
NK cells were first isolated from PBMCs using 
EasySep™ Human NK cell enrichment kit (STEMCELL 
biotechnology). The magnetically isolated NK cells 
were stained with anti-CD3 FITC, anti-CD56 Pe-Cy7 
and LIVE/DEAD® red stain for a further enrichment, 
whereby the CD3 negative and CD56 positive live cells 
were sorted with MoFlo™ cell sorter (Beckman Coulter). 
The purity of all the sorted NK population was around 
99% of CD3 negative and CD56 positive lymphocytes. 
The sorted NK cell populations were sent to AROS 
Applied Biotechnology A/S (Aarhus N, Denmark) as 
dry cell pellets. Total RNA was extracted, labelled and 
hybridized to GeneChip® Human Transcriptome Array 
2.0 (Affymetrix, USA). Microarray data are available in 
the ArrayExpress database (www.ebi.ac.uk/arrayexpress) 
under accession number E-MTAB-4403. Raw data 
was processed using Affymetrix’s Expression Console 
software using default RMA parameters. Statistical 
analysis of expression data and heatmap generation was 
performed using d-CHIP software (http://www.dchip.
org). The T test in d-CHIP is Welch modified two-sample 
t-test. Multiple comparison adjustment was carried out 
to include permutation to make sure the median FDR 
(False Discovery Rate) was < 5%. Venn diagrams were 
constructed from up or downregulated gene expression in 
B-CLL or Patients with SLL compared to HD.
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